Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard H Feldman

Showing results (81-90 of 161) with videos related to

Pageof 17
Sort By:
Neurology|September 4, 2020
Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adultsAlexandra J Weigand, Mark W Bondi, Kelsey R Thomas, et al.
Neurodegenerative Disease Management|May 20, 2026
Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's diseaseJeffrey L Cummings, Alireza Atri, Mary Sano, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 22, 2022
Home EEG sleep assessment shows reduced slow-wave sleep in mild-moderate Alzheimer's diseaseBrianne A Kent, Amelia A Casciola, Sebastiano K Carlucci, et al.
ACS Pharmacology & Translational Science|October 18, 2024
Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer's Disease TherapeuticsBen Boyarko, Sonia Podvin, Barry Greenberg, et al.
Annals of the New York Academy of Sciences|April 24, 2014
Alzheimer's disease research and development: a call for a new research roadmapHoward H Feldman, Magali Haas, Sam Gandy, et al.
Alzheimer'S Research & Therapy|November 23, 2024
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217Branislav Kovacech, Nicholas C Cullen, Petr Novak, et al.
Dementia and Geriatric Cognitive Disorders|September 13, 2006
Outcomes of cognitively impaired not demented at 2 years in the Canadian Cohort Study of Cognitive Impairment and Related DementiasGing-Yuek R Hsiung, Alan Donald, Jacob Grand, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 16, 2013
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's diseaseMaria C Carrillo, H Robert Brashear, Veronika Logovinsky, et al.
Dementia and Geriatric Cognitive Disorders|April 18, 2008
Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohortGing-Yuek R Hsiung, Sina Alipour, Claudia Jacova, et al.
Pharmacogenetics and Genomics|March 13, 2008
Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's diseaseRoger Lane, Howard H Feldman, Joanne Meyer, et al.
Pageof 17

Showing results (81-90 of 161) with videos related to

Sort By:
Pageof 17
Neurology|September 4, 2020
Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adultsAlexandra J Weigand, Mark W Bondi, Kelsey R Thomas, et al.
Neurodegenerative Disease Management|May 20, 2026
Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's diseaseJeffrey L Cummings, Alireza Atri, Mary Sano, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 22, 2022
Home EEG sleep assessment shows reduced slow-wave sleep in mild-moderate Alzheimer's diseaseBrianne A Kent, Amelia A Casciola, Sebastiano K Carlucci, et al.
ACS Pharmacology & Translational Science|October 18, 2024
Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer's Disease TherapeuticsBen Boyarko, Sonia Podvin, Barry Greenberg, et al.
Annals of the New York Academy of Sciences|April 24, 2014
Alzheimer's disease research and development: a call for a new research roadmapHoward H Feldman, Magali Haas, Sam Gandy, et al.
Alzheimer'S Research & Therapy|November 23, 2024
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217Branislav Kovacech, Nicholas C Cullen, Petr Novak, et al.
Dementia and Geriatric Cognitive Disorders|September 13, 2006
Outcomes of cognitively impaired not demented at 2 years in the Canadian Cohort Study of Cognitive Impairment and Related DementiasGing-Yuek R Hsiung, Alan Donald, Jacob Grand, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 16, 2013
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's diseaseMaria C Carrillo, H Robert Brashear, Veronika Logovinsky, et al.
Dementia and Geriatric Cognitive Disorders|April 18, 2008
Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohortGing-Yuek R Hsiung, Sina Alipour, Claudia Jacova, et al.
Pharmacogenetics and Genomics|March 13, 2008
Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's diseaseRoger Lane, Howard H Feldman, Joanne Meyer, et al.
Pageof 17